Investigation of in vitro Cytotoxicity of Chelidonium majus against Leishmania Major

Document Type : Original Articles


1 Biomedical Engineering Department, University of Karbala, Karbala, Iraq

2 Al-Manara College For Medical Sciences, Maysan, Iraq

3 Anesthesia Techniques, Al–Nisour University College, Baghdad, Iraq

4 College of Technical Engineering, The Islamic University, Najaf, Iraq

5 Department of Optics Techniques, Dijlah University College, Al-Masafi Street, Al-Dora, Baghdad 00964, Iraq

6 Anesthesia Techniques Department, Al-Mustaqbal University College, Babylon, Iraq

7 Medical Physics Department, Hilla University College, Babylon, Iraq

8 Scientific Research Center, Al-Ayen University, Thi-Qar, Iraq

9 Altoosi University College, Najaf, Iraq

10 Department of Nursing, Al-Zahrawi University College, Karbala, Iraq

11 Al-Esraa University College, Baghdad, Iraq


One of the public health issues in the endemic areas, especially in the Middle East region would be the Leishmaniasis. The suggested cure for leishmaniasis is pentavalent antimonials. These medications have drastic side effects and the risk of relapse. On the other hand, nowadays use of herbal remedies as safe and cost-effective treatments have been increased. Therefore this study was designed to determine in vitro anti-leishmanial activity of methanol extracts of greater celandine (Chelidonium majus) against Leishmania major. Greater celandine extract was added to L. major promastigotes and intra-macrophagic amastigotes. After 24, 48 and 72 h in vitro culture the percentage of promastigotes viability was calculated by direct counting method and MTT assay. Cytotoxicity in intra-macrophagic amastigotes was evaluated by direct counting method. Viability in minimum dose and maximum dose-treated groups (1.5 and 90 μg/ml) after 24 h, was 55.52% and 36.34%, respectively. After 48 h, it was 40% and 25.26% and after 72 h, it was 62.18% and 38.45%, respectively. The half maximal inhibitory concentration (IC50) was 0.92 μg/ml, after 24 h. Cytotoxicity in intra-macrophagic amastigotes treated by 3 μg/ml dose after 24 and 48 h, was 33.23% and 50.34%, respectively. It could be concluded that greater celandine methanolic extract has in vitro cytotoxic effect on the L. major in time and dose-dependent pattern.


Main Subjects

  1. Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007;7(9):581-96.
  2. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49(1):50.
  3. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis. 2007;5(3):150-8.
  4. Croft SL, Coombs GH. Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003;19(11):502-8.
  5. Corns CM. Herbal remedies and clinical biochemistry. Ann Clin Biochem. 2003;40(5):489-507.
  6. Zuo GY, Meng FY, Hao XY, Zhang YL, Wang GC, Xu GL. Antibacterial alkaloids from Chelidonium majus Linn (Papaveraceae) against clinical isolates of methicillin-resistant Staphylococcus aureus. J Pharm Pharm Sci. 2008;11(4):90-4.
  7. Meng F, Zuo G, Hao X, Wang G, Xiao H, Zhang J, et al. Antifungal activity of the benzo [c] phenanthridine alkaloids from Chelidonium majus Linn against resistant clinical yeast isolates. J Ethnopharmacol. 2009;125(3):494-6.
  8. Krizhanovska V, Sile I, Kronberga A, Nakurte I, Mezaka I, Dambrova M, et al. The Cultivation of Chelidonium majus L. Increased the Total Alkaloid Content and Cytotoxic Activity Compared with Those of Wild-Grown Plants. Plants. 2021;10(9):1971.
  1. Patil AD, Aphale PS, Sharma DB, Bhonde RR. Can homeopathic medicine Chelidonium majus serve a dual role of an anti-obesity and anti-diabetic agent? Med Hypotheses. 2022;159:110749.
  2. Colombo ML, Bosisio E. Pharmacological activities ofchelidonium majusl.(papaveraceae). Pharmacol Res. 1996;33(2):127-34.
  3. Barreto MC, Pinto RE, Arrabaça JD, Pavão ML. Inhibition of mouse liver respiration by Chelidonium majus isoquinoline alkaloids. Toxicol Lett. 2003;146(1):37-47.
  4. Sylvester PW. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Drug design and discovery: Springer; 2011. p. 157-68.
  5. Maji AK, Banerji P. Chelidonium majus L.(Greater celandine)–a review on its phytochemical and therapeutic perspectives. Int J Herb Med. 2015;3(1):10-27.
  6. Yao J-Y, Zhou Z-M, Pan X-y, Hao G-j, Li X-L, Xu Y, et al. In vivo anthelmintic activity of chelidonine from Chelidonium majus L. against Dactylogyrus intermedius in Carassius auratus. Parasitol Res. 2011;109(5):1465-9.
  7. Cheng R, Chen X, Liu S, Zhang X, Zhang G. Experimental study of the inhibitory effects of Chelidonium majus L. extractive on Streptococcus mutans in vitro. Shanghai Kou Qiang Yi Xue = Shanghai J. Stomatol. 2006;15(3):318-20.

16.          Miao F, Yang X-J, Zhou L, Hu H-J, Zheng F, Ding X-D, et al. Structural modification of sanguinarine and chelerythrine and their antibacterial activity. Nat Prod Res. 2011;25(9):863-75.